![]() ![]() A dual SGLT-1/SGLT-2 inhibitor shines in Type 1 diabetesĪlso in September (September was an encouraging month for type 1 diabetics), Lexicon Pharmaceuticals (NASDAQ: LXRX) announced that its experimental dual inhibitor of SGLT-1 and SGLT-2 met its mark in a phase 3 trial for type 1 diabetes. This setup could dramatically reduce instances of hypoglycemia and greatly improve the quality of life of type 1 diabetics, who no longer have to constantly check their blood sugar throughout the day. It uses a sensor with a protruding needle that's slipped under the skin to measure insulin levels, while a pump worn on the abdomen delivers insulin as needed. The device, which was approved for those aged 14 and up, measures a patient's blood glucose every five minutes. One of the most exciting advances of 2016 was the FDA's approval in September of Medtronic's ( MDT 1.38%) MiniMed 670G, the world's first artificial pancreas for type 1 diabetes. In no particular order, here are the 12 greatest medical breakthroughs of 2016. Of course, some medical breakthroughs, be they approvals or ongoing clinical trials, stood head-and-shoulders above the rest in 2016. With tens of billions of dollars invested in research and development annually, it's reassuring to see that money paying off in life-changing medications and devices. Meanwhile, the regulatory agency has also given the green light to 25 new medical devices this year. ![]() Food and Drug Administration has approved 19 novel drugs in 2016 to treat everything from psoriasis to hepatitis C to cancer. ![]() ![]() With less than two weeks to go before we turn the page on 2016, we can look back on another largely successful year for the healthcare industry. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |